Transcend Capital Advisors’s Calithera Biosciences, Inc CALA Stock Holding History

Transcend Capital Advisors’s Portfolio CALA Stock Details CALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-739	Closed	-$6K	–	553
2022 Q1	$6K	Hold	739	–	–	﹤0.01%	515
2021 Q4	$10K	Sell	739 -750	-50%	-$18.8K	﹤0.01%	488
2021 Q3	$57K	Buy	1,489 +500	+51%	+$21.6K	0.01%	482
2021 Q2	$41K	Sell	989 -250	-20%	-$11K	0.01%	322
2021 Q1	$59K	Sell	1,239 -750	-38%	-$43.6K	0.01%	410
2020 Q4	$195K	Buy	1,989 +750	+61%	+$65.7K	0.03%	355
2020 Q3	$85K	Buy	+1,239	New	+$108K	0.02%	258

Other funds holding CALA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Transcend Capital Advisors's CALA Position: Q2 2022 in Review

Transcend Capital Advisors sold out of Calithera Biosciences, Inc (CALA) in Q2 2022, closing a stake of 739 shares — an estimated $6K sold.

Transcend Capital Advisors first reported a position in CALA in Q3 2020 and held it in 7 quarters. The position peaked at $195K in Q4 2020. 28 funds tracked by Wall St. Rank hold CALA as of Q2 2022.

Transcend Capital Advisors reported no remaining Calithera Biosciences, Inc position as of Q2 2022 after selling out during the quarter.
Transcend Capital Advisors sold 739 Calithera Biosciences, Inc shares in Q2 2022, an estimated $6K.
Transcend Capital Advisors first reported a position in Calithera Biosciences, Inc in Q3 2020 and held it in 7 quarters.
Transcend Capital Advisors's Calithera Biosciences, Inc position peaked at $195K in Q4 2020.
28 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2022.

Based on Transcend Capital Advisors's 13F filing for Q2 2022, filed 12 Jul 2022.